Şunu aradınız:: limfoproliferattiv (Maltaca - İngilizce)

tumuri u mard limfoproliferattiv
malignancies and lymphoproliferative disorders

disturb limfoproliferattiv wara t-trapjant
post transplant lymphoproliferative disorder

kien irrapportat disturb limfoproliferattiv assoċjat ma 'ebv.
ebv-associated lymphoproliferative disorder has been reported.

tumuri malinni u mard limfoproliferattiv wara t-trapjant
malignancies and post-transplant lymphoproliferative disease

immunosuppressjoni eċċessiva b’ riskju ta ’ mard limfoproliferattiv.
excessive immunosuppression with risk of lymphoproliferative disease.

disturb limfoproliferattiv ta’ wara t-trapjant (ptld)
post-transplant lymphoproliferative disorder (ptld)

mard limfoproliferattiv mill-ebv (virus ta’ epstein-barr)
ebv (epstein-barr virus) lymphoproliferative disease

ciclosporin, tacrolimus: immunosuppressjoni eċċessiva b’riskju ta’ mard limfoproliferattiv.
ciclosporin, tacrolimus: excessive immunosuppression with risk of lymphoproliferative disease.

pazjenti li qed jieħdu tacrolimus dehru li żviluppaw disturbi limfoproliferattiv marbutin ma ’ l- ebv.
patients treated with tacrolimus have been reported to develop ebv-associated lymphoproliferative disorders.

Ġie rrapportat li t-twaqqif tal-immunosuppressjoni jista' jipprovdi rigressjoni parzjali tad-disturb limfoproliferattiv.
it has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder.

pazjenti fuq terapija immunosoppressiva wara trapjant huma f’riskju ikbar li jiżviluppaw mard limfoproliferattiv (lpds) u infezzjonijiet opportunistiċi.
patients on immunosuppressive therapy following transplantation are at increased risk for developing lymphoproliferative disorders (lpds) and opportunistic infections.

disturbi limfoproliferattivi il-kura b’xaluprine żżidlek ir-riskju li jkollok tip ta’ kanċer li jissejjaħ disturb limfoproliferattiv.
lymphoproliferative disorders treatment with xaluprine increases your risk of getting a type of cancer called lymphoproliferative disorder.

pazjenti li kellhom trapjant li qed jirċievu kura immunosoppressiva b’ korsijiet flimkien ma ’ basiliximab jew mingħajru għandhom riskju akbar li jiżviluppaw mard limfoproliferattiv (lpds)
in a pooled analysis of two

marbuta mal-kura b’tacrolimus ġew rapportati neoplażmi beninji kif ukoll malinji li jinkludu disturbi limfoproliferattiv assoċjati ma’ ebv kif ukoll tkabbir malinn fil-ġilda.
benign as well as malignant neoplasms including ebv-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment.

fi studju ieħor li fih kienu rreġistrati pazjenti ta ’ ≤20 sena li kellhom trapjant tal- kliewi li kien maħsub biex jevalwa s- sigurtà ta ’ twaqqif progressiv tal- kortikosterojdi (li beda sitt xhur wara t- trapjant) minn kors immunosoppressiv li nbeda mat- trapjant li kien jinkludi immunosoppressjoni b’ doża sħiħa kemm b’ rapamune kif ukoll b’ impeditur ta ’ calcineurin flimkien ma ’ induzzjoni ta ’ basiliximab, mill- 274 pazjent li rreġistraw, 19 (6. 9%) kienu rrappurtati li żviluppaw disturb limfoproliferattiv ta ’ wara t - trapjant (ptld).
in another study enrolling renal transplant patients  20 years of age that was intended to assess the safety of progressive corticosteroid withdrawal (beginning at six months post-transplantation) from an immunosuppressive regimen initiated at transplantation that included full-dose immunosuppression with both rapamune and a calcineurin inhibitor in combination with basiliximab induction, of the 274 patients enrolled, 19 (6.9%) were reported to have developed post-transplant lymphoproliferative disorder (ptld).